Clinical Trial Detail

NCT ID NCT02906696
Title Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic myeloid leukemia

Therapies

Bosutinib

Age Groups: senior adult

No variant requirements are available.